- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.12.24 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2024/25 | 1 | HKEx | ||
| 17.12.24 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2024/25 | - | HKEx | ||
| 17.12.24 | EXTRAWELL PHAR (00858): INTERIM REPORT 2024/25 | - | HKEx | ||
| 29.11.24 | EXTRAWELL PHAR (00858): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024 | 3 | HKEx | ||
| 19.11.24 | EXTRAWELL PHAR (00858): PROFIT ALERT | - | HKEx | ||
| 14.11.24 | EXTRAWELL PHAR (00858): DATE OF BOARD MEETING | 1 | HKEx | ||
| 15.10.24 | EXTRAWELL PHAR (00858): COMPLETION OF MAJOR TRANSACTION IN RELATION TO THE EXTENSION OF LOAN AGREEMENT AND PROVISION OF FINANCIAL ASSISTANCE | - | HKEx | ||
| EXTRAWELL PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 15.10.24 | EXTRAWELL PHAR (00858): POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 15 OCTOBER 2024 | 1 | HKEx | ||
| 26.09.24 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF CIRCULAR CONTAINING NOTICE OF SPECIAL ... | - | HKEx | ||
| 26.09.24 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF CIRCULAR CONTAINING NOTICE OF SPECIAL ... | - | HKEx | ||
| 26.09.24 | EXTRAWELL PHAR (00858): NOTICE OF SPECIAL GENERAL MEETING | 1 | HKEx | ||
| 26.09.24 | EXTRAWELL PHAR (00858): FORM OF PROXY FOR SPECIAL GENERAL MEETING TO BE HELD ON TUESDAY, 15 OCTOBER 2024 AT 11:00 A.M. | - | HKEx | ||
| 26.09.24 | EXTRAWELL PHAR (00858): MAJOR TRANSACTION IN RELATION TO THE EXTENSION OF LOAN AGREEMENT AND PROVISION OF FINANCIAL ASSISTANCE AND NOTICE OF SPECIAL GENERAL ... | - | HKEx | ||
| 13.09.24 | EXTRAWELL PHAR (00858): DELAY IN DESPATCH OF CIRCULAR IN RELATION TO THE MAJOR TRANSACTION EXTENSION OF LOAN AGREEMENT AND PROVISION OF FINANCIAL ASSISTANCE | - | HKEx |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 32,130 | +3,31 % | Ionis Pharmaceuticals, Inc.: Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome | Positive End of Phase 2 discussion with FDA, including alignment on Phase 3 design
Bayley-4 expressive communication selected as Phase 3 study primary endpoint
... ► Artikel lesen | |
| CSPC PHARMA | 0,589 | +5,14 % | Die Aktie der CSPC Pharmaceutical Group läuft schlechter: Große Kursverluste! (0,582 €) | Zu den großen Verlierern am Aktienmarkt zählt heute die CSPC Pharmaceutical Group-Aktie . Der Titel verbilligt sich am Freitag deutlich. Mit einem Verlust von 5,52 Prozent gehört heute der Anteilsschein... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 17,335 | +0,03 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,184 | +7,44 % | SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL | - Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients - - Median Overall... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 304,10 | +1,43 % | Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6.8% Following Insider Selling | ||
| CATALYST PHARMACEUTICALS | 21,360 | +0,28 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,090 | -2,72 % | ENZON PHARMACEUTICALS, INC. - 10-K, Annual Report | ||
| OPUS GENETICS | 1,018 | +8,53 % | Opus Genetics gets FDA Fast Track designation for Phentolamine Ophthalmic Solution | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line | Northvale, New Jersey--(Newsfile Corp. - March 3, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,011 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 10.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.02.2025ISIN NameES0105015012 LAR... ► Artikel lesen | |
| SAVARA | 2,240 | +0,90 % | Savara Reports Third Quarter 2024 Financial Results and Provides Business Update | LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 1,240 | -13,29 % | Galectin Therapeutics Inc.: Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH | In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value While there was a favorable trend for incidence of varices in the primary end point intent-to-treat... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 2,910 | -9,91 % | Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Sees Large Increase in Short Interest | ||
| SCICLONE PHARMACEUTICALS | - | - | Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone | TOKYO, Feb 28, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company has entered into a license agreement granting the exclusive development and distribution rights for the fibroblast... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 0,610 | 0,00 % | NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results | EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2024.
"Avenova sales through... ► Artikel lesen |
EXTRAWELL PHARMACEUTICAL HOLDINGS LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXTRAWELL PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.
